Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Lethal factor toxemia and anti-protective antigen antibody activity in naturally acquired cutaneous anthrax.

Boyer AE, Quinn CP, Beesley CA, Gallegos-Candela M, Marston CK, Cronin LX, Lins RC, Stoddard RA, Li H, Schiffer J, Hossain MJ, Chakraborty A, Rahman M, Luby SP, Shieh WJ, Zaki S, Barr JR, Hoffmaster AR.

J Infect Dis. 2011 Nov;204(9):1321-7. doi: 10.1093/infdis/jir543. Epub 2011 Sep 9.

2.

The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.

Brenneman KE, Doganay M, Akmal A, Goldman S, Galloway DR, Mateczun AJ, Cross AS, Baillie LW.

FEMS Immunol Med Microbiol. 2011 Jul;62(2):164-72. doi: 10.1111/j.1574-695X.2011.00800.x. Epub 2011 Apr 15.

3.

Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax.

Semenova VA, Schmidt DS, Taylor TH Jr, Li H, Steward-Clark E, Soroka SD, Ballard MM, Quinn CP.

Vaccine. 2007 Feb 26;25(10):1780-8. Epub 2006 Nov 27.

PMID:
17229495
4.

Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax.

Quinn CP, Dull PM, Semenova V, Li H, Crotty S, Taylor TH, Steward-Clark E, Stamey KL, Schmidt DS, Stinson KW, Freeman AE, Elie CM, Martin SK, Greene C, Aubert RD, Glidewell J, Perkins BA, Ahmed R, Stephens DS.

J Infect Dis. 2004 Oct 1;190(7):1228-36. Epub 2004 Aug 30.

PMID:
15346332
5.

A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.

Quinn CP, Sabourin CL, Niemuth NA, Li H, Semenova VA, Rudge TL, Mayfield HJ, Schiffer J, Mittler RS, Ibegbu CC, Wrammert J, Ahmed R, Brys AM, Hunt RE, Levesque D, Estep JE, Barnewall RE, Robinson DM, Plikaytis BD, Marano N; AVRP Laboratory Working Group.

Clin Vaccine Immunol. 2012 Nov;19(11):1730-45. doi: 10.1128/CVI.00324-12. Epub 2012 Aug 29.

6.

Characterization of the native form of anthrax lethal factor for use in the toxin neutralization assay.

Lu H, Catania J, Baranji K, Feng J, Gu M, Lathey J, Sweeny D, Sanford H, Sapru K, Patamawenu T, Chen JH, Ng A, Fesseha Z, Kluepfel-Stahl S, Minang J, Alleva D.

Clin Vaccine Immunol. 2013 Jul;20(7):986-97. doi: 10.1128/CVI.00046-13. Epub 2013 May 1.

7.

Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.

Dumas EK, Garman L, Cuthbertson H, Charlton S, Hallis B, Engler RJM, Choudhari S, Picking WD, James JA, Farris AD.

Vaccine. 2017 Jun 8;35(26):3416-3422. doi: 10.1016/j.vaccine.2017.05.006. Epub 2017 May 11.

PMID:
28504191
8.

Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.

Crowe SR, Garman L, Engler RJ, Farris AD, Ballard JD, Harley JB, James JA.

Vaccine. 2011 May 9;29(20):3670-8. doi: 10.1016/j.vaccine.2011.03.011. Epub 2011 Mar 21.

9.

Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen.

Quinn CP, Semenova VA, Elie CM, Romero-Steiner S, Greene C, Li H, Stamey K, Steward-Clark E, Schmidt DS, Mothershed E, Pruckler J, Schwartz S, Benson RF, Helsel LO, Holder PF, Johnson SE, Kellum M, Messmer T, Thacker WL, Besser L, Plikaytis BD, Taylor TH Jr, Freeman AE, Wallace KJ, Dull P, Sejvar J, Bruce E, Moreno R, Schuchat A, Lingappa JR, Martin SK, Walls J, Bronsdon M, Carlone GM, Bajani-Ari M, Ashford DA, Stephens DS, Perkins BA.

Emerg Infect Dis. 2002 Oct;8(10):1103-10.

10.

Quantitative anti-PA IgG ELISA; assessment and comparability with the anthrax toxin neutralization assay in goats.

Ndumnego OC, Crafford J, Beyer W, van Heerden H.

BMC Vet Res. 2013 Dec 27;9:265. doi: 10.1186/1746-6148-9-265.

11.

Serological studies of patients with cutaneous and oral-oropharyngeal anthrax from northern Thailand.

Sirisanthana T, Nelson KE, Ezzell JW, Abshire TG.

Am J Trop Med Hyg. 1988 Dec;39(6):575-81.

PMID:
3144920
12.

Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.

Grunow R, Porsch-Ozcürümez M, Splettstoesser W, Buckendahl A, Hahn U, Beyer W, Böhm R, Huber M, vd Esche U, Bessler W, Frangoulidis D, Finke EJ.

Vaccine. 2007 May 4;25(18):3679-83. Epub 2007 Jan 23.

PMID:
17287051
13.

A field usable qualitative anti-protective antigen enzyme-linked immunosorbent assay for serodiagnosis of human anthrax.

Ghosh N, Tomar I, Goel AK.

Microbiol Immunol. 2013 Feb;57(2):145-9. doi: 10.1111/1348-0421.12014.

14.

Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination.

Cao S, Guo A, Liu Z, Tan Y, Wu G, Zhang C, Zhao Y, Chen H.

Infect Immun. 2009 Oct;77(10):4679-87. doi: 10.1128/IAI.00264-09. Epub 2009 Jul 20.

15.

A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax.

Gorantala J, Grover S, Goel D, Rahi A, Jayadev Magani SK, Chandra S, Bhatnagar R.

Vaccine. 2011 Jun 15;29(27):4521-33. doi: 10.1016/j.vaccine.2011.03.082. Epub 2011 Apr 17.

PMID:
21504775
16.

Serodiagnosis of human cutaneous anthrax in India using an indirect anti-lethal factor IgG enzyme-linked immunosorbent assay.

Ghosh N, Tomar I, Lukka H, Goel AK.

Clin Vaccine Immunol. 2013 Feb;20(2):282-6. doi: 10.1128/CVI.00598-12. Epub 2012 Dec 26.

17.

Detoxified lethal toxin as a potential mucosal vaccine against anthrax.

Xu Q, Zeng M.

Clin Vaccine Immunol. 2008 Apr;15(4):612-6. doi: 10.1128/CVI.00402-07. Epub 2008 Feb 6.

18.

Role of toxin functional domains in anthrax pathogenesis.

Brossier F, Weber-Levy M, Mock M, Sirard JC.

Infect Immun. 2000 Apr;68(4):1781-6.

19.

Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.

Parreiras PM, Sirota LA, Wagner LD, Menzies SL, Arciniega JL.

Vaccine. 2009 Jul 16;27(33):4537-42. doi: 10.1016/j.vaccine.2009.05.045. Epub 2009 Jun 6.

PMID:
19501205
20.

Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis.

Pittman PR, Leitman SF, Oro JG, Norris SL, Marano NM, Ranadive MV, Sink BS, McKee KT Jr.

Clin Diagn Lab Immunol. 2005 Jun;12(6):713-21.

Supplemental Content

Support Center